Previous 10 | Next 10 |
The subsector with the best value and quality scores is pharmaceutical/biotechnology. Life science tools and healthcare equipment are the most overvalued. Fast facts on IDNA. A list of cheap stocks. For further details see: IDNA: Healthcare Dashboard For February
LEXINGTON, Mass. and AMSTERDAM, Feb. 07, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the dosing of the first two patients in its European open-label Phase ...
Final Analysis of Pivotal HOPE-B Study Demonstrates Durable and Sustained Therapeutic Effect of Etranacogene Dezaparvovec Gene Therapy in Hemophilia B - Data Presented at EAHAD 2022 - Data from the largest gene therapy study in Hemophilia B to date shows that etranacogene dezapa...
Investors were all spooked today with Dow plummeting more than 500 points. The primary cause can be attributed to inflation fears, disappointing earnings, and booming bond yields. Tech stocks drove the Dow down with the NASDAQ skidding 2.6 percent and the S&P 500 index falling 1.8 percent...
Alnylam Pharmaceuticals (NASDAQ:ALNY), Crispr Therapeutics (NASDAQ:CRSP), Karuna Therapeutics (NASDAQ:KRTX) and six other biopharma names are among potential M&A candidates for 2022, according to Goldman Sachs. The nine new names have been added to Goldman Sach's Healthcare Strategic Asse...
Pharma/biotech is the most attractive subsector. The most overvalued one is life science tools. IXJ: an alternative to XLV. 10 stocks cheaper than their peers in December. For further details see: IXJ: Healthcare Dashboard For December
Gainers: Adagio (NASDAQ:ADGI) +101%. Kaixin (NASDAQ:KXIN) +34%. Calliditas (NASDAQ:CALT) +25%. Euro Tech Holdings (NASDAQ:CLWT) +19%. Mechel (NYSE:MTL) +17%. Processa (NASDAQ:PCSA) +17%. Versus Systems (NASDAQ:VS) +17%. Assertio (NASDAQ:ASRT) +17%. Zai Lab (NASDAQ:ZLAB) +17%. Petros Pharmaceu...
Gainers: Adagio Therapeutics (NASDAQ:ADGI) +68%, Calliditas Therapeutics (NASDAQ:CALT) +28%, Assertio (NASDAQ:ASRT) +17%, Aptose Biosciences (NASDAQ:APTO) +16%, Arcturus Therapeutics (NASDAQ:ARCT) +15%. Losers: uniQure (NASDAQ:QURE) -25%, Regi...
uniQure (NASDAQ:QURE) announces initial observations on the first four patients enrolled in the lower-dose cohort of its Phase I/II clinical trial of AMT-130 for the treatment of Huntington’s disease. Shares up 2.5% premarket at $29.47. Two of the four enrolled patients ...
~ Treatment was well tolerated with no significant safety issues related to AMT-130 in first two treated patients through one year of follow-up ~ ~ Neurofilament Light Chain (NfL) rose as expected immediately following surgery and returned to baseline in treated patients ~ ~...
News, Short Squeeze, Breakout and More Instantly...
~ uniQure maintains preferential access to industry-leading manufacturing capabilities to support its pipeline of gene therapy candidates ~ ~ Immediate reduction in cash burn, projected to save $40 million annually ~ LEXINGTON, Mass. and AMSTERDAM, July 23, 2024 (GLOBE NEWSWIRE) -...
A look at the top 10 most actives in the United States Kazia Therapeutics Limited (KZIA) rose 248.0% to $0.6682 on volume of 430,252,408 shares Maxeon Solar Technologies Ltd. (MAXN) fell 15.0% to $0.2108 on volume of 237,403,092 shares NVIDIA Corporation (NVDA) rose 2.7% to $134.91 on vol...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) rose 2.5% to $131.38 on volume of 280,159,738 shares Maxeon Solar Technologies Ltd. (MAXN) fell 8.1% to $0.248 on volume of 217,585,873 shares Tesla Inc. (TSLA) rose 3.7% to $262.33 on volume of 159,323,492 s...